Skip Navigation

TSET Health Promotion Research Center Expands to Tulsa

NEWS

TSET Health Promotion Research Center Expands to Tulsa


By

Date

April 30, 2024

Media Contact

Diane Sarantakos
(405) 630-7835
Diane-Sarantakos@ouhsc.edu


TULSA, OKLA. – The TSET Health Promotion Research Center (HPRC), a component of OU Health Stephenson Cancer Center, is expanding to the OU-Tulsa campus. The expansion will provide an additional site for HPRC’s mission of reducing the burden of disease in Oklahoma by addressing modifiable health risk factors such as tobacco use, sedentary lifestyle, poor diet, cancer screening and risky alcohol and substance use through research, novel intervention development, and dissemination of research findings.

Stephenson Cancer Center, Oklahoma’s only National Cancer Institute-Designated Cancer Center, recently announced its expansion to Tulsa to bring NCI-level care and clinical trials to people throughout northeastern Oklahoma. The work of HPRC, supported by the cancer center and the Oklahoma Tobacco Settlement Endowment Trust (TSET), complements Stephenson’s mission with its research and educational programs.

HPRC-Tulsa will ultimately be staffed by 12 faculty members and additional support staff. Hiring has begun, and five new faculty members will begin work this fall. They will occupy offices and shared laboratory space at the Schusterman Center in midtown Tulsa at 41st and Yale. Currently, HPRC has 27 faculty members — five in Tulsa and 22 in Oklahoma City.

In collaboration with HPRC faculty in Oklahoma City, HPRC-Tulsa will support a substantial increase in health promotion research in northeastern Oklahoma. HPRC-Tulsa plans to recruit researchers with expertise in areas such as Native American health inequities, cancer survivorship (including pain), community-engaged research (especially with rural communities), physical activity, obesity, nutrition, opioid misuse, health behavior change (especially around smoking, substance use, physical activity and diet), and health services/implementation science.

The Tulsa site will also be the home of an advanced pain research laboratory supporting the work of Jamie Rhudy, Ph.D., OU’s site director for HPRC-Tulsa, and his collaborators. Rhudy, a professor of health promotion science in the OU Hudson College of Public Health, has over 25 years of research experience in affective neuroscience, studying how the brain processes emotions, specifically focusing on the interface of emotion and pain processing. His research examines the psychological, sociological/environmental, and biological mechanisms that contribute to chronic pain risk.

For the past decade, Rhudy’s work has focused on understanding health risk mechanisms in Native Americans. Nearly one in three Native Americans reports experiencing chronic pain and approximately one in seven reports chronic pain that disables them on most days.  

Jamie Rhudy, Ph.D.

About the University of Oklahoma

Founded in 1890, the University of Oklahoma is a public research university located in Norman, Oklahoma. As the state’s flagship university, OU serves the educational, cultural, economic and health care needs of the state, region and nation. OU was named the state’s highest-ranking university in U.S. News & World Report’s most recent Best Colleges list. For more information about the university, visit ou.edu.


Recent News

Impact
July 30, 2026

OU Marks Historic Milestone in Weather Forecasting with Launch of Oklahoma 3D Mesonet

The National Weather Service has, for the first time, purchased vertical atmospheric profiles collected by drones — data collected by the University of Oklahoma (OU) and Meteomatics. The milestone is the next step forward for the Oklahoma 3D Mesonet.


Research
July 30, 2026

OU Researcher Joins $12 Million Effort to Advance Obesity Drug Discovery

A University of Oklahoma researcher is part of an international team developing a new way to discover obesity drugs using human cells instead of animal models, an approach that could speed the development of more effective and affordable treatments. The effort is supported by a $12 million grant from the Novo Nordisk Foundation.